Lilly swoops on Dermira to claim Dupixent rivalEli Lilly agreed on Friday to buy dermatology specialist Dermira for $1.1 billion and its lead drug, a Share XLilly swoops on Dermira to claim Dupixent rivalhttps://pharmaphorum.com/news/lilly-swoops-on-dermira-to-claim-dupixent-rival/
Regeneron/Sanofi get EU okay for Dupixent in “asthma of the sinuses”Regeneron and Sanofi’s immunology drug Dupixent has been approved for a third indication in Europe, adding the treatment Share XRegeneron/Sanofi get EU okay for Dupixent in “asthma of the sinuses”https://pharmaphorum.com/news/regeneron-sanofi-get-eu-okay-for-dupixent-in-asthma-of-the-sinuses/
Pfizer’s Xeljanz follow-up abrocitinib gathers momentumPfizer has reported new data with abrocitinib, a follow-up to its JAK inhibitor Xeljanz, which is facing increased Share XPfizer’s Xeljanz follow-up abrocitinib gathers momentumhttps://pharmaphorum.com/news/pfizers-xeljanz-follow-up-abrocitinib-gathers-momentum/
Sanofi’s Dupixent backed for nasal polyps use in EuropeSanofi and Regeneron’s fast-growing immunology drug Dupixent is on course for a third indication in Europe after being Share XSanofi’s Dupixent backed for nasal polyps use in Europehttps://pharmaphorum.com/news/sanofis-dupixent-backed-for-nasal-polyps-use-in-europe/
Novartis backs brolucizumab with new head-to-head Eylea trialNovartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Share XNovartis backs brolucizumab with new head-to-head Eylea trialhttps://pharmaphorum.com/news/novartis-backs-brolucizumab-with-new-head-to-head-eylea-trial/
TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?Cardiologists only had to wait a few days after The Medicines Company teased top-line results with its cholesterol-lowering Share XTMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?https://pharmaphorum.com/news/tmcs-inclisiran-impresses-at-esc-but-will-it-surpass-pcsk9-rivals/
Regeneron preps for 2020 filing for new cholesterol drug after trial successRegeneron has announced data that could create a niche for its latest cholesterol drug evinacumab in a small Share XRegeneron preps for 2020 filing for new cholesterol drug after trial successhttps://pharmaphorum.com/news/evinacumab-regeneron-cholesterol-drug-trial/
First effective Ebola treatment a step closer after breakthrough trialClinical trials of four experimental treatments for Ebola in the Congo have been halted early after two of Share XFirst effective Ebola treatment a step closer after breakthrough trialhttps://pharmaphorum.com/news/ebola-virus-clinical-trial-breakthrough/
Almirall takes option on Dermira’s eczema drug lebrikizumabSpain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, Share XAlmirall takes option on Dermira’s eczema drug lebrikizumabhttps://pharmaphorum.com/news/almirall-takes-option-on-dermiras-eczema-drug-lebrikizumab/
